Study to Investigate the Absolute Bioavailability of Oral Sylibin
Launched by FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSITARIO RAMON Y CAJAL · Dec 14, 2015
Trial Information
Current as of June 13, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Healthy individuals men who give their written consent to participate in the study, after having received information about the design, the project objectives, the risks and that at any moment they can refuse their cooperation.
- • Understand the purpose of the study and be available for performing hospital visits and and admissions.
- • Age between 18 and 45 years.
- • Healthy subjects, without any organic or psychological pathology
- • Clinical history and physical examination within normal limits.
- • Lack of clinically relevant abnormalities in blood test (hematology, biochemistry, virology) and urine test
- • Vital signs and electrocardiographic recording in the normal range.
- • Males with childbearing potential partners must agree to use a highly effective method of contraception (such as surgical sterilization, double barrier method) from the moment of signing the informed consent until 6 months after the end of their participation in the study.
- Exclusion Criteria:
- • Subjects suffering from organic or psychological pathology. Prior to the inclusion of any volunteer it should be considered all security parameters mentioned in the protocol (biochemical markers of kidney damage and / or liver out of the normal range set by the laboratory).
- • Subjects who have received prescription drug treatment in the last 15 days or any medication within 48 hours before receiving study medication.
- • Subjects with a BMI that is not between 18 and 30.
- • Known hypersensitivity to any drug
- • Suspected of drug abuse
- • Consumers of alcohol daily and / or acute alcohol poisoning in the last week.
- • Subjects smoking.
- • Have donated blood in the last three months.
- • Participation in any other investigational drug study in the previous 3 months
- • Not to be able to follow instructions or collaborate during the course of the study.
About Fundacion Para La Investigacion Biomedica Del Hospital Universitario Ramon Y Cajal
The Fundación para la Investigación Biomédica del Hospital Universitario Ramón y Cajal is a leading research organization dedicated to advancing biomedical science and enhancing patient care through innovative clinical trials. Located in Madrid, Spain, the foundation collaborates closely with healthcare professionals and academic institutions to facilitate cutting-edge research initiatives. Its mission is to foster a multidisciplinary approach to medical research, focusing on translating scientific discoveries into effective therapeutic strategies. By prioritizing patient safety and ethical standards, the foundation aims to contribute significantly to the global body of medical knowledge and improve health outcomes.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Trial Officials
Mónica Aguilar, MD
Principal Investigator
Hospital Universitario Ramon y Cajal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials